S&P 500   4,585.59
DOW   36,117.38
QQQ   390.43
Forward dividend yield: What it is and how to use it 
An Unusual Way to Invest in Gold (Ad)
What are consumer staples stocks?
Healthcare sector: Overview and keys to investing
New CBOE “special perk” helps traders target income every weekend (Ad)
Is Amazon a blue chip stock?
How to find penny stocks to invest and trade 
New CBOE “special perk” helps traders target income every weekend (Ad)
How to invest in GTE technology: A guide 
Consumer staples vs. consumer discretionary
S&P 500   4,585.59
DOW   36,117.38
QQQ   390.43
Forward dividend yield: What it is and how to use it 
An Unusual Way to Invest in Gold (Ad)
What are consumer staples stocks?
Healthcare sector: Overview and keys to investing
New CBOE “special perk” helps traders target income every weekend (Ad)
Is Amazon a blue chip stock?
How to find penny stocks to invest and trade 
New CBOE “special perk” helps traders target income every weekend (Ad)
How to invest in GTE technology: A guide 
Consumer staples vs. consumer discretionary
S&P 500   4,585.59
DOW   36,117.38
QQQ   390.43
Forward dividend yield: What it is and how to use it 
An Unusual Way to Invest in Gold (Ad)
What are consumer staples stocks?
Healthcare sector: Overview and keys to investing
New CBOE “special perk” helps traders target income every weekend (Ad)
Is Amazon a blue chip stock?
How to find penny stocks to invest and trade 
New CBOE “special perk” helps traders target income every weekend (Ad)
How to invest in GTE technology: A guide 
Consumer staples vs. consumer discretionary
S&P 500   4,585.59
DOW   36,117.38
QQQ   390.43
Forward dividend yield: What it is and how to use it 
An Unusual Way to Invest in Gold (Ad)
What are consumer staples stocks?
Healthcare sector: Overview and keys to investing
New CBOE “special perk” helps traders target income every weekend (Ad)
Is Amazon a blue chip stock?
How to find penny stocks to invest and trade 
New CBOE “special perk” helps traders target income every weekend (Ad)
How to invest in GTE technology: A guide 
Consumer staples vs. consumer discretionary

Akoustis Technologies Stock Price, News & Analysis (NASDAQ:AKTS)

$0.57
-0.01 (-1.72%)
(As of 12/7/2023 ET)
Compare
Today's Range
$0.55
$0.61
50-Day Range
$0.48
$0.89
52-Week Range
$0.46
$4.96
Volume
548,221 shs
Average Volume
732,671 shs
Market Capitalization
$41.31 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$2.38

Akoustis Technologies MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
316.7% Upside
$2.38 Price Target
Short Interest
Bearish
9.52% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Selling Shares
$12,604 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.72) to ($0.39) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.08 out of 5 stars

Computer And Technology Sector

330th out of 591 stocks

Telephone & Telegraph Apparatus Industry

1st out of 5 stocks


AKTS stock logo

About Akoustis Technologies Stock (NASDAQ:AKTS)

Akoustis Technologies, Inc., through its subsidiary, Akoustis, Inc., designs, develops, manufactures, and sells radio frequency (RF) filter products for the mobile wireless device industry in the United States, Asia, Europe, and internationally. It operates through Foundry Fabrication Services and RF Filters segments. The Foundry Fabrication Services segment provides engineering review and backend packaging services. Its RF Filters segment sells amplifier and filter products. It offers RF filters for mobile wireless devices, such as smartphones and tablets, cellular infrastructure equipment, Wi-Fi customer premise equipment, and military and defense applications. The company was founded in 2013 and is headquartered in Huntersville, North Carolina.

AKTS Stock Price History

AKTS Stock News Headlines

Akoustis Awarded Phase 2 For DARPA COFFEE Program
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Craig-Hallum Keeps Their Buy Rating on Akoustis Technologies (AKTS)
Akoustis, Inc.: Akoustis Reports First Quarter FY24 Results
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Akoustis Technologies Shares Drop on Weak 4Q Results
Roth MKM Remains a Buy on Akoustis Technologies (AKTS)
Craig-Hallum Sticks to Its Buy Rating for Akoustis Technologies (AKTS)
Earnings Outlook For Akoustis Technologies
AKTS - Akoustis Technologies, Inc.
Akoustis Technologies (NASDAQ: AKTS)
See More Headlines
Receive AKTS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Akoustis Technologies and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/13/2023
Today
12/07/2023
Next Earnings (Estimated)
2/06/2024
Fiscal Year End
6/30/2024

Industry, Sector and Symbol

Industry
Telephone & telegraph apparatus
Sub-Industry
N/A
Current Symbol
NASDAQ:AKTS
Fax
N/A
Employees
222
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$2.38
High Stock Price Target
$3.00
Low Stock Price Target
$1.75
Potential Upside/Downside
+316.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

Net Income
$-63,560,000.00
Net Margins
-226.21%
Pretax Margin
-234.57%

Debt

Sales & Book Value

Annual Sales
$27.12 million
Book Value
$1.20 per share

Miscellaneous

Free Float
68,425,000
Market Cap
$41.31 million
Optionable
Not Optionable
Beta
1.68
Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report














AKTS Stock Analysis - Frequently Asked Questions

Should I buy or sell Akoustis Technologies stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Akoustis Technologies in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" AKTS shares.
View AKTS analyst ratings
or view top-rated stocks.

What is Akoustis Technologies' stock price target for 2024?

2 Wall Street research analysts have issued 12-month target prices for Akoustis Technologies' shares. Their AKTS share price targets range from $1.75 to $3.00. On average, they predict the company's share price to reach $2.38 in the next twelve months. This suggests a possible upside of 316.7% from the stock's current price.
View analysts price targets for AKTS
or view top-rated stocks among Wall Street analysts.

How have AKTS shares performed in 2023?

Akoustis Technologies' stock was trading at $2.82 on January 1st, 2023. Since then, AKTS stock has decreased by 79.8% and is now trading at $0.57.
View the best growth stocks for 2023 here
.

When is Akoustis Technologies' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 6th 2024.
View our AKTS earnings forecast
.

How were Akoustis Technologies' earnings last quarter?

Akoustis Technologies, Inc. (NASDAQ:AKTS) released its earnings results on Monday, November, 13th. The technology company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.18) by $0.09. The technology company earned $7 million during the quarter, compared to analysts' expectations of $7.09 million. Akoustis Technologies had a negative trailing twelve-month return on equity of 71.24% and a negative net margin of 226.21%.

What guidance has Akoustis Technologies issued on next quarter's earnings?

Akoustis Technologies updated its second quarter 2024 earnings guidance on Monday, November, 13th. The company provided EPS guidance of for the period. The company issued revenue guidance of $8.30 million-$8.80 million, compared to the consensus revenue estimate of $7.19 million.

What other stocks do shareholders of Akoustis Technologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Akoustis Technologies investors own include Inseego (INSG), NVIDIA (NVDA), Block (SQ), Editas Medicine (EDIT), Marvell Technology (MRVL), Alibaba Group (BABA), Invitae (NVTA), Advanced Micro Devices (AMD), CRISPR Therapeutics (CRSP) and JD.com (JD).

Who are Akoustis Technologies' major shareholders?

Akoustis Technologies' stock is owned by a variety of retail and institutional investors. Top institutional investors include Senvest Management LLC (5.26%), Perkins Capital Management Inc. (0.83%), UBS Group AG (0.59%), Commonwealth Equity Services LLC (0.30%), Crestwood Advisors Group LLC (0.15%) and Connors Investor Services Inc. (0.15%). Insiders that own company stock include Arthur Geiss, David Aichele, James Michael Mcguire, Jeffrey B Shealy, Kenneth Boller, Rohan Houlden, Steven Denbaars and Suzanne B Rudy.
View institutional ownership trends
.

How do I buy shares of Akoustis Technologies?

Shares of AKTS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:AKTS) was last updated on 12/8/2023 by MarketBeat.com Staff

My Account -